253.05
Bio Rad Laboratories Inc stock is traded at $253.05, with a volume of 33,332.
It is down -0.94% in the last 24 hours and down -9.78% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$254.32
Open:
$254.35
24h Volume:
33,332
Relative Volume:
0.10
Market Cap:
$6.77B
Revenue:
$2.59B
Net Income/Loss:
$168.80M
P/E Ratio:
41.66
EPS:
6.0748
Net Cash Flow:
$357.20M
1W Performance:
-2.30%
1M Performance:
-9.78%
6M Performance:
-19.59%
1Y Performance:
+5.55%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BIO
Bio Rad Laboratories Inc
|
253.05 | 6.81B | 2.59B | 168.80M | 357.20M | 6.0748 |
|
ABT
Abbott Laboratories
|
84.11 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
284.54 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
75.89 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
53.41 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
79.20 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Bio‑Rad expands TrailBlazer kits for antibody conjugation to StarBright dyes - SelectScience
A Look At Bio-Rad (BIO) Valuation After Q1 2026 Net Loss And Outlook Cut - Sahm
Bio-Rad Laboratories Inc. Class A (BIO) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Bio-Rad to Participate in Upcoming Investor ConferencesMay 8, 2026 - BioSpace
Dna Forensic Market Is Booming So Rapidly | Agilent Technologies, Illumina, Bio-Rad Laboratories - openPR.com
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN
Bio-Rad Laboratories, Inc. Q1 2026 earnings preview - MSN
Bio-Rad (BIO) Q2 2025 Earnings Call Transcript - AOL.com
Plasma ELISA Kit Market Size Expanding at 8.1% CAGR | By Key - openPR.com
Bio-Rad Launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers - the-scientist.com
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Common Stock (NY: BIO - FinancialContent
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out - Insider Monkey
Bio-Rad expands range of TrailBlazer Kits for Antibody Conjugation to StarBright Dyes - Cambridge Network
MSN Money - MSN
Bio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab Manager
Bio-Rad Exceeds Earnings Expectations in Second Quarter 2025 - HarianBasis.co
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Bio-Rad reports net loss of USD 527.1M in Q1 2026 - Medical Buyer
Bio-Rad Laboratories, Inc. (BIO) Investor Outlook: Navigating The 11.58% Potential Upside - DirectorsTalk Interviews
Medical Biosensors Market is expected to Hit US$ 12.60 Billion - openPR.com
Bio Rad Laboratories (BIO) EPS Loss Revives Concerns Over Volatile Profit Narratives - Sahm
Comerica Bank Has $3.74 Million Stake in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad expands antibody portfolio for biologics bioanalysis and drug monitoring - Laboratory Talk
Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold - Moomoo
Bio-Rad Laboratories Inc (BIO) Stock Down 8.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Bio-Rad Laboratories Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Why Bio-Rad Laboratories Is Plunging 10.8%: Wells Fargo Maintains Equal-Weight - AlphaStreet
Bio-Rad Laboratories stock falls on lowered revenue outlook By Investing.com - Investing.com Canada
Bio-Rad drops 10.2% as guidance cut and Sartorius valuation hit overshadow Q1 results - Quiver Quantitative
Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings - MarketBeat
Bio-Rad Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bio-Rad Laboratories Q1 2026 Earnings Call Transcript - MarketBeat
Bio-Rad Laboratories Inc (BIO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Bio-Rad (BIO) Q1 2026 Earnings Transcript - The Globe and Mail
Bio-Rad Laboratories Q1 Earnings Call Highlights - MarketBeat
BIO SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Bio-Rad Reports First-Quarter 2026 Financial Results - BioSpace
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds By Investing.com - Investing.com Canada
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results - MarketBeat
Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus
Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):